Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaborat...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Timothé Ménard, Kyle Young, Laura Siegel, Jennifer Emerson, Robert Studt, Leslie Sidor, The IMPALA Industry Group
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/4f25ca3e1e574d46be9aacf06152718e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f25ca3e1e574d46be9aacf06152718e
record_format	dspace
spelling	oai:doaj.org-article:4f25ca3e1e574d46be9aacf06152718e2021-11-19T15:35:29ZCross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group2163-830610.1002/psp4.12677https://doaj.org/article/4f25ca3e1e574d46be9aacf06152718e2021-08-01T00:00:00Zhttps://doi.org/10.1002/psp4.12677https://doaj.org/toc/2163-8306Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaboration span the sharing of knowledge and ideas, the sharing of analytics methods, discussion of talent upskilling and technology adoption strategies, and collaborative discussion on these potential changes with global Health Authorities.Timothé MénardKyle YoungLaura SiegelJennifer EmersonRobert StudtLeslie SidorThe IMPALA Industry GroupWileyarticleTherapeutics. PharmacologyRM1-950ENCPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 799-803 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Timothé Ménard Kyle Young Laura Siegel Jennifer Emerson Robert Studt Leslie Sidor The IMPALA Industry Group Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
description	Quality functions from pharmaceutical sponsor companies aim to increase the use of analytics in their oversight of Good Clinical Practices and Pharmacovigilance activities. To leverage and accelerate progress, several companies decided to establish a collaborative model. The goals of this collaboration span the sharing of knowledge and ideas, the sharing of analytics methods, discussion of talent upskilling and technology adoption strategies, and collaborative discussion on these potential changes with global Health Authorities.
format	article
author	Timothé Ménard Kyle Young Laura Siegel Jennifer Emerson Robert Studt Leslie Sidor The IMPALA Industry Group
author_facet	Timothé Ménard Kyle Young Laura Siegel Jennifer Emerson Robert Studt Leslie Sidor The IMPALA Industry Group
author_sort	Timothé Ménard
title	Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_short	Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_full	Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_fullStr	Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_full_unstemmed	Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group
title_sort	cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: the impala industry group
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/4f25ca3e1e574d46be9aacf06152718e
work_keys_str_mv	AT timothemenard crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup AT kyleyoung crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup AT laurasiegel crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup AT jenniferemerson crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup AT robertstudt crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup AT lesliesidor crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup AT theimpalaindustrygroup crosscompanycollaborationtoleverageanalyticsforclinicalqualityandacceleratedrugdevelopmenttheimpalaindustrygroup
_version_	1718420011532419072

Cross‐company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

Ejemplares similares